Market Need HelixBind focuses on rapid, accurate blood infection diagnostics to improve sepsis outcomes and antimicrobial stewardship, indicating a strong value proposition for hospitals, ICUs, and microbiology laboratories seeking faster decision support and reduced LOS.

Targeted Opportunities With a small team size and a focus on clinical deployment, prioritize direct outreach to mid to large hospitals, academic medical centers, and health systems that run high sepsis, bloodstream infection, or Lyme disease programs to maximize pilot and expansion opportunities.

Strategic Partnerships Leverage relationships and credibility from NIH and CARB-X funding history and LymeX recognition to approach government-funded research centers, translational science programs, and public health collaborations for co-development or grant-supported pilots.

Clinical Advisory Highlight the addition of clinical experts and advisory board members as a signal of scientific credibility to potential customers, enabling faster stakeholder buy-in from infectious disease physicians, microbiologists, and hospital procurement teams.

Tech & Integration Emphasize cloud-enabled, scalable diagnostics and compatibility with common web technologies and deployment models to support integrations with existing lab information systems and workflows, reducing barriers to adoption in hospital settings.